Lymphangiosarcoma is a rare and aggressive cancer that develops in body parts affected by long-term swelling, usually following breast cancer treatment. Though uncommon today due to changes in surgical techniques, understanding this condition remains crucial for those living with chronic lymphatic system blockage.

Understanding Lymphangiosarcoma and Its Rarity

Lymphangiosarcoma is a rare form of cancer that emerges in areas where the body experiences long-standing lymphedema, which is swelling caused by obstruction of the lymphatic system. Despite its name suggesting it originates from lymphatic vessels, research indicates this cancer actually arises from endothelial cells, which line blood vessels. This is why some medical experts consider “angiosarcoma” to be a more accurate term for this condition.^[1]

The disease most commonly affects people who have survived breast cancer, particularly those who underwent aggressive surgical treatment decades ago. When lymphangiosarcoma develops following breast surgery and the resulting lymphedema, it carries the specific name Stewart-Treves syndrome, named after the doctors who first described this pattern in 1948.^[4] This connection highlights how a complication of one cancer treatment can, unfortunately, lead to another serious health challenge years later.

Although lymphangiosarcoma can occur in any limb affected by chronic swelling, it has a strong preference for the upper extremities. The arms, forearms, elbows, and chest wall are the most typical locations where this cancer appears. Less commonly, it can develop in the lower limbs when they experience prolonged lymphatic obstruction.^[1]

Epidemiology: How Common Is This Cancer?

Lymphangiosarcoma is exceptionally rare, making it unfamiliar to many healthcare providers and challenging to study comprehensively. Around 300 cases have been reported worldwide since the condition was first formally described in the medical literature.^[7] This rarity means that even large medical centers may encounter only a handful of cases over many years.

In the mid-20th century, when radical mastectomy was the standard treatment for breast cancer, the incidence of lymphangiosarcoma in patients who survived at least five years after surgery ranged from 0.07% to 0.45%.^[4] These percentages may seem small, but they represented a meaningful number of patients given how common breast cancer was and how aggressive the surgical approach had been. The procedure involved removing not just the breast tissue but also the lymph nodes and channels under the arm, leading to severe, permanent lymphedema in many women.

Today, lymphangiosarcoma following breast cancer treatment has become vanishingly rare. This dramatic decline occurred because surgical practices changed significantly in the late 1960s and early 1970s. The radical mastectomy was replaced with more conservative procedures like the modified radical mastectomy and, more recently, with segmental breast tissue removal combined with radiation therapy. These modern approaches cause lymphedema much less frequently, which in turn means fewer cases of lymphangiosarcoma.^[1]

The disease predominantly affects women, largely because of its historical association with breast cancer treatment. However, men and women with lymphedema from other causes can also develop this cancer. Approximately 90% of lymphangiosarcoma cases arise in individuals who have long-standing lymphedema, regardless of its cause.^[3]

Causes and Origins of Lymphangiosarcoma

The development of lymphangiosarcoma represents a devastating late complication of massive, chronic lymphedema. For decades, doctors and researchers have worked to understand exactly how prolonged swelling transforms into cancer, but the complete picture remains elusive. What we do know is that the cancer emerges years after the lymphedema begins, typically appearing between five and fifteen years following the initial injury or surgery that caused the swelling.^[3]

Historically, lymphangiosarcoma was most commonly linked to the classical Halstedian radical mastectomy, an extensive surgical procedure used to treat breast cancer. During this operation, surgeons removed the entire breast along with the axillary (armpit) lymph nodes and lymphatic channels. This comprehensive removal of lymphatic structures often led to massive, permanent swelling of the arm on the affected side. The chronic nature of this swelling created conditions that, in a small percentage of patients, eventually gave rise to cancer.^[1]

Several theories have been proposed to explain how lymphedema leads to cancer development. The original researchers, Stewart and Treves, suggested that a cancer-causing agent might be present in lymphedematous limbs. This theory proposed that something in the accumulated fluid or altered tissue environment could trigger malignant transformation over time.^[1]

Another prominent theory focuses on local immune system dysfunction. Researchers including Schreiber proposed that lymphedema creates what they called an “immunologically privileged site” within the affected limb. In simple terms, the chronic swelling and disrupted lymphatic drainage might impair the immune system’s ability to patrol and protect that area effectively. This reduced immune surveillance could allow abnormal cells to survive and multiply when they would normally be identified and destroyed by the body’s defenses.^[1] Experimental evidence supports this concept, showing that skin grafts placed on lymphedematous arms survive longer than those on healthy arms, suggesting weakened immune responses.

The role of radiation therapy in causing lymphangiosarcoma remains debated. Some cases have occurred in patients who received radiation treatment to the breast and underarm area, and radiation is known to damage blood vessels and cause scarring that worsens lymphedema. However, not all patients who develop lymphangiosarcoma received radiation, and most radiation-induced cancers in the chest wall are not specifically lymphangiosarcomas, making this connection unclear.^[5]

Risk Factors: Who Is at Greater Risk?

The primary and most significant risk factor for developing lymphangiosarcoma is having chronic, long-standing lymphedema. This swelling must persist for years, creating the conditions under which the cancer might eventually emerge. The longer the lymphedema persists and the more severe it becomes, the higher the theoretical risk, though the overall probability remains very low.^[3]

Women who underwent radical mastectomy for breast cancer represent the historically most affected group. For these patients, several factors interact to increase risk. The surgery itself removes crucial lymphatic structures that normally drain fluid from the arm. If radiation therapy was also administered to the chest and underarm, it can cause additional scarring and fibrosis of remaining lymphatic vessels, further impairing drainage and worsening swelling.^[3] The combination of surgical removal and radiation damage creates particularly severe, intractable lymphedema.

Beyond post-surgical lymphedema, other forms of chronic swelling can also lead to lymphangiosarcoma, though less commonly. People born with congenital lymphedema conditions, such as Milroy disease, carry some risk throughout their lives. Lymphedema caused by trauma, chronic infections, or parasitic diseases like filariasis can similarly create the conditions for cancer development decades later.^[5]

Patients who have survived breast cancer for five or more years and who have severe lymphedema face particular concern. This timeframe represents the typical latency period during which cellular changes might progress from normal tissue through precancerous states to frank malignancy. The cancer frequently appears as what doctors call “sarcomatous degeneration” in these long-term survivors.^[1]

Symptoms and Clinical Presentation

Lymphangiosarcoma announces its presence through distinctive changes in the skin of the affected, swollen limb. The initial signs often appear deceptively benign, which can lead to delays in recognition and diagnosis. Understanding what to watch for becomes crucial for anyone living with chronic lymphedema.^[2]

The cancer typically begins as a purple discoloration or bruised-looking area on the skin. This purple or reddish-purple appearance is quite characteristic and stands out against the often pale, stretched skin of a chronically swollen limb. Some patients notice a tender nodule or lump beneath the skin rather than just discoloration. These initial lesions usually appear on the anterior (front) surface of the affected extremity, most commonly in the upper arm, forearm, or elbow region.^[1]

As the disease progresses, these seemingly minor skin changes evolve into more obvious problems. The purple areas may expand and develop into painful, open sores. These sores often have a crusted appearance and fail to heal despite normal wound care. Eventually, extensive necrosis, meaning death of skin and underlying tissue, develops at the site. The cancer invades not just the skin surface but also the subcutaneous tissue (the fat and connective tissue beneath the skin).^[1]

Multiple smaller spots, sometimes called “satellite lesions,” may appear around the original site. These represent local spread of the cancer and indicate its aggressive nature. The affected area might also ulcerate and bleed, particularly as the tumor breaks through the skin surface.^[2]

For patients who have undergone mastectomy, lymphangiosarcoma most frequently develops in the upper arm, forearm, elbow, and anterior chest wall. About 60% of all lymphangiosarcomas occur on the skin of the arms or legs, with particular concentration in the forearm and elbow areas. In different populations, the disease can also affect the scalp of older men or the head and neck of older women, though these patterns relate to different underlying causes of lymphedema.^[3]

One of the most concerning characteristics of lymphangiosarcoma is its tendency to metastasize, or spread, quickly. The cancer doesn’t remain localized for long. It frequently spreads to distant organs, with the lungs being the most common site of metastatic disease. The liver and bones can also become involved. This rapid progression contributes significantly to the poor outcomes associated with this malignancy.^[3]

Prevention Strategies

The most effective approach to preventing lymphangiosarcoma involves preventing or minimizing the chronic lymphedema that creates the conditions for this cancer to develop. While complete prevention isn’t always possible, several strategies can reduce risk substantially.^[9]

For patients with breast cancer, modern surgical techniques represent the single most important preventive measure. The shift away from radical mastectomy toward more conservative surgical approaches has dramatically reduced the incidence of severe post-surgical lymphedema. Modified radical mastectomy, lumpectomy with radiation, and sentinel lymph node biopsy techniques all preserve more lymphatic structures than the old radical approach, resulting in much less frequent and less severe swelling.^[1]

For individuals who already have lymphedema from any cause, proper management of the swelling becomes paramount. Effective lymphedema management includes several key components. Compression therapy using specially fitted garments helps prevent fluid accumulation and reduces swelling. Manual lymphatic drainage, a specialized massage technique, can help move trapped fluid out of affected areas. Regular exercise, when done appropriately, promotes lymph flow and overall limb health. Meticulous skin care prevents the infections and injuries that can worsen lymphedema.^[9]

Preventing and promptly treating complications of lymphedema also plays a role in prevention. Conditions like erysipelas (a bacterial skin infection) and deep vein thrombosis (blood clots in deep veins) commonly occur with chronic lymphedema and can worsen the swelling. Regular examination of affected areas helps identify these complications early, when treatment is most effective.^[9]

Perhaps most importantly, vigilant monitoring for any skin changes in lymphedematous limbs allows for early detection of lymphangiosarcoma if it does develop. Any new purple discoloration, tender nodules, sores that don’t heal, or unusual skin changes should prompt immediate medical evaluation. Early biopsy of suspicious lesions provides the best chance for successful treatment, as catching the cancer in its earliest stages offers higher rates of long-term survival.^[9]

Pathophysiology: What Happens in the Body

Understanding what happens inside the body as lymphangiosarcoma develops helps explain both the disease’s behavior and its grim prognosis. The pathophysiological changes begin with the chronic lymphedema itself and progress through multiple stages to become an aggressive cancer.^[4]

Chronic lymphedema creates a profoundly altered tissue environment in the affected limb. The normal flow of lymphatic fluid becomes severely impaired or completely blocked, leading to accumulation of protein-rich fluid in the tissues. This stagnant fluid causes progressive tissue changes, including thickening and fibrosis (scarring) of the skin and deeper structures. The tissue becomes increasingly abnormal over years and decades of persistent swelling.^[1]

Within this abnormal environment, several processes may contribute to cancer development. The chronic inflammatory state associated with long-standing lymphedema produces continuous signals for tissue repair and new blood vessel formation. Growth factors and cytokines (signaling molecules) that normally promote healing are present at elevated levels for extended periods. While these signals are meant to be temporary and carefully regulated, their persistent activation in lymphedematous tissue may eventually lead to uncontrolled cell growth.^[5]

The local immune dysfunction theory suggests that lymphatic obstruction impairs the immune system’s ability to survey and protect the affected area. Normally, immune cells circulate through tissues via the lymphatic system, identifying and eliminating abnormal or cancerous cells. When lymphatic drainage is severely compromised, this surveillance becomes less effective, potentially allowing malignant cells to survive and proliferate when they would otherwise be destroyed.^[1]

When lymphangiosarcoma develops, it arises from endothelial cells, which are the cells that line blood vessels. Despite the disease’s name suggesting lymphatic origin, evidence indicates that blood vessel endothelium, rather than lymphatic vessel lining, gives rise to these tumors. This is why the alternative name “angiosarcoma” more accurately describes the cellular origin.^[1]

Once established, lymphangiosarcoma behaves as a highly aggressive, high-grade malignancy. The tumor grows rapidly through local tissues, destroying skin, subcutaneous fat, and potentially deeper structures. It has a strong propensity for both local spread and distant metastasis. Tumor cells readily enter the bloodstream and travel to distant organs, particularly the lungs. This aggressive biological behavior, combined with the cancer’s tendency to recur even after apparently complete removal, explains the poor survival rates associated with this disease.^[3]

The cancer progresses through the skin structures, causing the characteristic purple discoloration as tumor cells infiltrate dermal blood vessels. As growth continues, the tumor outgrows its blood supply, leading to central necrosis where tissue death occurs in the middle of the lesion. This necrosis produces the crusting, ulceration, and breakdown of skin that characterizes advanced lymphangiosarcoma. The extensive tissue destruction and rapid progression make this one of the most aggressive soft tissue sarcomas.^[1]